.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX67_Tagraxofusp.Tagraxofusp .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX67_Tagraxofusp.Tagraxofusp| name: | Tagraxofusp | |
| ATC code: | L01XX67 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 12 | mg |
| volume of distribution: | 6.5 | L |
| clearance: | 2.5 | L/h |
| other parameters in model implementation | ||
Tagraxofusp (SL-401) is a fusion protein consisting of human interleukin-3 (IL-3) fused to a truncated diphtheria toxin. It is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Tagraxofusp is approved for adult and pediatric patients 2 years and older with BPDCN.
Pharmacokinetics in adult patients with BPDCN, after intravenous infusion. Values primarily reflect population PK analyses from clinical studies.